Limbic encephalitis is an autoimmune disorder characterized by inflammation of the brain with rapidly progressing dementia which requires definitive neurological evaluation. We describe both clinical as well as imaging findings in a case of limbic encephalitis using positron emission tomography/magnetic resonance imaging.
Introduction
Autoimmune limbic encephalitis is an autoimmune-mediated inflammation typically affecting the medial temporal lobes and other limbic structures (cingulate gyrus, orbital cortex, and hypothalamus). [1] Patients affected usually show rapidly progressive short-term memory deficits, psychiatric symptoms, and seizures. Final diagnosis requires either neuropathological or neuroradiological interventions for the involvement of the limbic system besides the typical clinical syndrome. We here present a clinical case of limbic encephalitis with findings of simultaneous positron emission tomography/magnetic resonance imaging (PET/MRI).
Case Report
A 47-year-old female presented with recurrent generalized myoclonic jerks worsening over a period of the past 6 months accompanied by progressive memory loss and worsening behavioral disturbances. Routine This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercialShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
For reprints contact: reprints@medknow.com nonneoplastic based on whether the antibodies are due to the presence of an underlying tumor, common tumors being squamous cell carcinoma lung, testicular germ cell tumor, and thymic, breast, renal, colonic, esophageal, ureteric bud, and ovarian carcinomas. [1] The nonneoplastic group of patients usually responds favorably to immunotherapy. [2] The diagnosis of autoimmune encephalitis requires to meet the following five criteria: (1) Subacute onset, (2) Bilateral brain abnormalities on T2 FLAIR MRI, highly restricted to medial temporal lobes, (3) CSF pleocytosis and detectable antibodies in CSF, (4) Abnormal EEG with epileptic or slow-wave activity on temporal lobe, and (5) Reasonable exclusion of other causes of encephalitis. [3] Definitive diagnosis is characterized by the presence of specific antibody in serum or CSF and response to immunotherapy. [4] On MRI, T2-weighted FLAIR images show hyperintensities with swelling usually restricted to the mesial-temporal cortex. Asymmetric bilateral involvement being most common (60%). Basal ganglia are also frequently involved with less common involvement of the lateral temporal lobe and insula. Contrast enhancement is rare with no diffusion restriction and hemorrhage.
Various studies have demonstrated hypermetabolism on PET even in MRI-negative or inconclusive cases. [5] FDG PET in autoimmune encephalitis usually shows hypermetabolism in the mesial temporal and orbitofrontal cortex, occipital hypometabolism, and symmetrical hypermetabolism in the corpus striatum and amygdala and may even resemble neurodegenerative disease in older patients. [6, 7] Although PET may help in identifying an underlying disease to some extent, the diagnosis of autoimmune limbic encephalitis is still challenging due to the varied presentation and nonspecific initial laboratory as well as imaging findings. Simultaneous PET/MRI combines high-resolution structural and functional information from multiparametric MRI along with metabolic information from PET to localize the abnormality, to rule out other primary abnormalities in the brain, and to identify any other malignancy in the body to rule out paraneoplastic limbic encephalitis. Although, both FDG PET and MRI have been used for the diagnostic intervention in autoimmune limbic encephalitis, simultaneous PET/MRI holds the dual advantage of providing PET and MRI in single temporal as well as spatial domain. Hence, the role of this imaging modality is instrumental and holds promise in diagnosis of aggregation-induced emission.
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